Showing 6781-6790 of 8583 results for "".
- Study: Tape Strips Can Assess Biomarkers in Pediatric ADhttps://practicaldermatology.com/news/study-tape-strips-can-assess-biomarkers-in-pediatric-ad-1/2460167/Tape strips may serve as a minimally invasive approach to assess biomarkers for early-onset pediatric atopic dermatitis (AD), finds a study in JAMA Dermatology. In the study of 51 children younger than 5 years, 21 children had moderate to severe AD with less than 6 months of di
- Burt's Bees: Data Support Efficacy of Natural Skincarehttps://practicaldermatology.com/news/burts-bees-data-support-efficacy-of-natural-skincare/2460166/Products and ingredients in the Burt’s Bees natural skincare line provide documented benefits, according to studies presented at the second annual Integrative Dermatology Symposium (IDS) in San Diego this month. Among the findings is evidenc
- FDA Approves Galderma's Aklief (trifarotene) Cream for Acnehttps://practicaldermatology.com/news/fda-approves-galdermas-aklief-trifarotene-cream-for-acne/2460164/The FDA has approved Galderma's Aklief (trifarotene) Cream, 0.005% for the topical treatment of acne. Aklief Cream is the only topical retinoid that selectively targets retinoic acid receptor (RAR) gamma, the most common RAR found in the skin. Trifarotene is the first new retinoid molecule to
- Industry News: Galderma Will Go It Alonehttps://practicaldermatology.com/news/industry-news-galderma-will-go-it-alone/2460161/It’s official. Galderma is going it alone after completion of CHF 10.2 billion acquisition of Nestlé Skin Health, first announced in May 2019. The acquisition, led by a consortium comprising the EQT VIII fund (“EQT”), Luxinva (a wholly-owned subsidiary of
- National Eczema Association's New Campaign Exposes The “Real Eczema”https://practicaldermatology.com/news/national-eczema-associations-new-campaign-exposes-the-real-eczema/2460160/October's Eczema Awareness Month efforts will focus on unhiding the realities of eczema with the National Eczema Association's (NEA) #TheRealEczema campaign. The new campaign includes a video, "The Real Eczema," featur
- Positive Top Line Results from Second Phase 3 Study of Abrocitinib for Atopic Dermatitishttps://practicaldermatology.com/news/positive-top-line-results-from-second-phase-3-study-of-abrocitinib-for-atopic-dermatitis-1/2460159/Pfizer Inc. shared positive top-line results from a second Phase 3 pivotal study evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis (AD). This is the second monotherap
- Neutrogena’s Newest Collection Addresses Dull, Uneven Skinhttps://practicaldermatology.com/news/neutrogenas-newest-collection-addresses-dull-uneven-skin/2460157/Nearly two-thirds (66 percent) of U.S. millennial women age 23-38 have noticed a shift in their skin's brightness, according to a poll of more 1,100 U.S. women aged 18 and older sponsored by Neutrogena. Neutrogena’s new four-part collection,
- Pediatric Dermatologist Who Co-Founded Camp for Children Recognized for Carehttps://practicaldermatology.com/news/pediatric-dermatologist-who-co-founded-camp-for-children-recognized-for-care/2460153/The American Academy of Dermatology honored dermatologist Karen Wiss, MD, FAAD, as a Patient Care Hero for her role in treating a patient with recessive dystrophic epidermolysis bullosa (RDEB). To support pediatric patients with isolating conditions like RDEB, Dr. Wiss, a derm
- L'Oréal USA Announces Winners Of 2019 Women In Digital Next Generation Awardshttps://practicaldermatology.com/news/loreal-usa-announces-winners-of-2019-women-in-digital-next-generation-awards/2460152/L'Oréal USA announced the winners of the 2019 Women in Digital NEXT Generation Awards. The three winners, each of whom will receive $25,000 in grant funding, include Mandi Nyambi and Lanya Olmsted, the co-founders of Baalm, an
- Positive Results for Aclaris Therapeutics’ A-101 45% Topical Solution in Pivotal Phase 3 Trial for the Treatment of Wartshttps://practicaldermatology.com/news/positive-results-for-aclaris-therapeutics-a-101-45-topical-solution-in-pivotal-phase-3-trial-for-the-treatment-of-warts/2460151/Aclaris Therapeutics, Inc., shared positive results from its Phase 3 clinical trial, THWART-2 (WART-302), of A-101 45% Topical Solution, an investigational new drug for the treatment of common warts (verruca vulgaris). A-101 45% Topical Solution met the